Pulmozyme Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Pulmozyme market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be credited to the expansion of reimbursement coverage, limited competition, demonstrated clinical efficacy, FDA approval, and clinical acceptance.

The projected growth for the forecast period is driven by the implementation of neonatal screening programs, increased investment in therapies for rare diseases, progress in genetic profiling, improvements in healthcare infrastructure, and advancements in genomics. Key trends in the forecast period include progress in homecare settings, innovations in drug delivery systems, integration of digital health technologies, development of patient-friendly formulations, and ongoing research in enzyme therapy.

The growing prevalence of respiratory disorders is expected to drive the expansion of the pulmozyme market in the coming years. Respiratory disorders are conditions that affect the lungs and airways, hindering breathing and oxygen exchange. These include diseases like asthma, COPD, and pneumonia. The rise in respiratory conditions is fueled by factors such as increasing air pollution, smoking, occupational hazards, climate change, and a higher prevalence of allergens and infectious diseases. Pulmozyme (dornase alfa) is used to manage conditions like cystic fibrosis by breaking down thick mucus in the lungs, improving airflow, and reducing the risk of infections. For example, in June 2024, the Australian Institute of Health and Welfare reported that around 8.5 million Australians, or 34% of the population, had chronic respiratory conditions. This includes an estimated 2.8 million people, or 11% of the population, with asthma and 638,000 people, or 2.5% of the population, with chronic obstructive pulmonary disease (COPD). As such, the increasing incidence of respiratory disorders is a key driver for the pulmozyme market.

The growing number of lung transplants is expected to contribute to the pulmozyme market's growth. A lung transplant involves replacing a diseased or failing lung with a healthy donor lung to treat severe respiratory failure or chronic lung diseases. The rise in lung transplants is attributed to the increasing prevalence of chronic respiratory diseases such as cystic fibrosis and COPD, improvements in surgical techniques, and advancements in post-transplant care that boost survival rates. Pulmozyme, a recombinant human DNase enzyme, helps lung transplant patients by breaking down thick mucus in their airways, reducing the risk of infections, and improving lung function. This aids in enhancing the patients' ability to breathe and maintain respiratory health after transplantation. For instance, in August 2023, the National Health Service (NHS) in the UK reported that the number of active lung and heart-lung transplants increased from 267 in 2022 to 302 in 2023. Therefore, the rise in lung transplant procedures supports the growth of the pulmozyme market.

The increase in healthcare expenditure is expected to drive the pulmozyme market in the future. Healthcare expenditure encompasses the total financial resources allocated to medical services, healthcare infrastructure, pharmaceuticals, and related activities. This spending is rising due to an aging population, the growing prevalence of chronic and lifestyle-related diseases, medical advancements, and broader access to healthcare. Higher healthcare expenditure benefits the Pulmozyme market by supporting the development, production, and distribution of this specialized enzyme therapy, ensuring its availability to cystic fibrosis patients, and facilitating reimbursement policies that make it more accessible. Additionally, it promotes ongoing research to enhance the drug's efficacy and expand its clinical applications. For example, a report from the UK’s Office for National Statistics published in May 2024 highlighted a 5.6% increase in healthcare expenditure from 2022 to 2023, compared to a 0.9% growth rate in 2022. The total long-term health and social care expenditure also rose by 2.8% in real terms in 2022. Hence, rising healthcare expenditure plays a significant role in driving the pulmozyme market.

Key player operating in the pulmozyme market is Roche Holding AG.

North America was the largest region in the pulmozyme market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmozyme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pulmozyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pulmozyme (Dornase alfa) is a recombinant human deoxyribonuclease I (DNase I) enzyme primarily used to treat cystic fibrosis (CF). It works by breaking down the DNA in thick mucus found in the lungs, reducing its viscosity and enhancing lung function. Administered through a nebulizer, Pulmozyme helps improve lung function, makes breathing easier, and lowers the likelihood of respiratory infections.

The primary uses of pulmozyme are for cystic fibrosis and respiratory tract infections. This genetic disorder leads to the buildup of thick, sticky mucus in the lungs and digestive system, causing breathing issues and frequent lung infections. Pulmozyme is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used in settings such as hospitals, clinics, and homecare environments.

The pulmozyme market research report is one of a series of new reports that provides pulmozyme market statistics, including pulmozyme industry global market size, regional shares, competitors with a pulmozyme market share, detailed pulmozyme market segments, market trends, and opportunities, and any further data you may need to thrive in the pulmozyme industry. This pulmozyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pulmozyme market consists of sales of inhalation solutions, nebulizer solutions, and injectable solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.